teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 10 Projects Releases Packages Wiki Activity Actions 1

extract: 2026-03-19-glp1-price-compression-international-generics-claim-challenge

Browse source 
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents 2026-03-19 04:30:23 +00:00
parent ad24357879
commit 251379bc14
2 changed files with 22 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

6
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -107,6 +107,12 @@ Value in Health modeling study shows Medicare saves $715M over 10 years with com
Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow only 2% after 12 months (vs 6% for non-users), with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This suggests the 'inflationary through 2035' claim may only apply to short-term payers, while long-term risk-bearers see net savings.
### Additional Evidence (challenge)
*Source: [[2026-03-19-glp1-price-compression-international-generics-claim-challenge]] | Added: 2026-03-19*
International generic competition beginning January 2026 (Canada patent expiry, immediate Sandoz/Apotex/Teva filings) creates price compression trajectory faster than 'inflationary through 2035' assumes. Oral Wegovy launched at $149-299/month (5-8x reduction vs $1,300/month injectable). China/India generics projected at $40-50/month by 2030. Aon 192K patient study shows break-even timing is highly price-sensitive: at $1,300/month, multi-year retention required; at $50-150/month, Aon data suggests cost savings within 12-18 months under capitation. The 'inflationary through 2035' conclusion holds at current US pricing but becomes invalid if international generic arbitrage and oral formulation competition compress effective prices to $50-150/month range by 2030. Scope qualification needed: claim is valid conditional on pricing trajectory assumptions that are now challenged by G7 patent cliff precedent.
---
Relevant Notes:

17
inbox/queue/2026-03-19-glp1-price-compression-international-generics-claim-challenge.md
View file

@ -7,10 +7,14 @@ date: 2026-03-19
domain: health
secondary_domains: [internet-finance]
format: synthesis
status: unprocessed
status: enrichment
priority: high
tags: [glp-1, generics, patent-cliff, price-trajectory, cost-effectiveness, kb-claim-challenge, scope-qualification]
flagged_for_rio: ["GLP-1 price compression changes the investment economics for risk-bearing health plans — shorter time horizon to net savings under capitation"]
processed_by: vida
processed_date: 2026-03-19
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
extraction_model: "anthropic/claude-sonnet-4.5"
---
## Content
@ -96,3 +100,14 @@ PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic catego
WHY ARCHIVED: This is a direct scope challenge to the existing claim. The GLP-1 patent cliff data (GeneOnline) is already in queue but unprocessed; this synthesis connects it to the Aon cost data and makes the scope challenge explicit for the extractor.
EXTRACTION HINT: Don't extract a new claim — update/scope-qualify the existing GLP-1 claim. The extractor should add a `challenged_by` reference and update the claim body with the price trajectory sensitivity analysis.
## Key Facts
- Canada semaglutide patents expired January 4, 2026 with immediate generic filings from Sandoz, Apotex, Teva
- Brazil and India GLP-1 patent expirations March 2026
- China has 17+ generic GLP-1 candidates in Phase 3 trials
- Oral Wegovy launched January 2026 at $149-299/month vs $1,300/month for injectable semaglutide
- Medicare negotiated semaglutide rate: $245/month
- US/Europe GLP-1 patents extend to 2031-2032
- Orforglipron (Lilly non-peptide oral GLP-1) potential approval Q2 2026
- Amycretin shows 22% weight loss without plateau in trials